Conference: Gene Therapy for Rare Disorders (GTRD), 2023
Precision will be at this year’s Gene Therapy for Rare Disorders on March 20-23, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.
Speaking Engagements
Detailed descriptions for each speaking engagement are included below.
- Precision ADVANCE will have a plenary speaking position on March 21, 2023, 8:30 – 9:00 am.
- Project Farma will be facilitating a plenary panel discussion ” Current Trends in Technical Operations for Rare Disorders” on March 21, 2023, 10:45 – 11:15 am.
- Project Farma’s Tony Khoury (EVP, Project Farma) will be joining the Manufacturing track panel discussion, “Capacity versus Capability – Moving Towards Innovative Manufacturing Processes,” on March 21, 2023, 11:15 – 11:45 am.
- Precision ADVANCE will hold a drinks reception on March 21, 2023, at 6:10 pm in the Grand & Liberty Ballroom.
Connect with our Advanced Therapy experts
- Visit us at booth 13 in the exhibition area
- Schedule in-person or virtual meetings by clicking here: https://bit.ly/precisionmedicinegrp
- Attend our ADVANCE-sponsored Drinks Reception on March 21, 2023, at 6:10 PM ET
—
Plenary Speaking Position: Successfully Launching a Gene Therapy with Cynthia Pussinen & Dave Lennon
Precision ADVANCE | March 21, 2023, 8:30 – 9AM ET
- Key Takeaways
- Identify active strategies to enable a smooth plan from preclinical development to commercialization
- New approaches for regulatory approval and commercialization
- Anticipating and overcoming potential hurdles specific to gene therapies
- The future of the industry
Speakers:
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- Cynthia Pussinen: Former CTO (Spark Therapeutics Inc.)
- Dave Lennon: CEO (Satellite Bio)
Panel Discussion: Current Trends in Technical Operations for Rare Disorders
Project Farma | March 21, 2023, 10:45-11:15AM ET
- Key Takeaways
- Current trends impacting manufacturing of gene therapies including capital markets, supply chain and technologies
- Shifts in technical operations as a result of current trends
- Opportunities and innovations in technical operations that can transform the industry
Speakers:
- [Moderator] Charlie Harper: Vice President, Consulting (Project Farma)
- Greg Gara: Senior Vice President (Project Farma)
- Tony Khoury: Executive Vice President (Project Farma)
- Eric Hacherl: Vice President, Manufacturing (Spark Therapeutics, Inc.)
Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Project Farma | March 21, 2023, 11:15 – 11:45AM ET
- Greg Gara: Senior Vice President (Project Farma) to join
Article: Weathering the Storm: Cell and Gene’s Economic Downturn
After record-setting milestones in fundraising over the past two years, the advanced therapy investment landscape is experiencing a natural correction. Precision’s Anshul Mangal and Dr. James M. Wilson outline in this The Medicine Maker article how industry leaders can ensure the advancement of innovative treatments for patients with #rarediseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.
Case Study: Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
New study demonstrates the feasibility of systematically integrating long-term survival estimates obtained from a formal expert elicitation study with empirical clinical trial data through a case study.
On-Demand: Let’s Talk: Moving CGTx Clinical Development Forward in 2023
Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).
Precision for Medicine CIR (French Research Tax Credit) Accreditation Updates
PARIS, FRANCE – 10 November 2022 — Precision for Medicine, the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, today announced that it has received updated CIR accreditation from the French Ministry of Higher Education and Research.
The French R&D tax credit initiative (‘Crédit d’Impôt Recherche’, CIR) gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D activities outsourced to Precision for Medicine.
Under this accreditation, the French Ministry of Higher Education and Research has also recognized Precision for Medicine’s Italian, German, Polish, Spanish, and Hungarian affiliates as reputable cross-border R&D experts.
Andrea Cotton-Berry, Precision for Medicine’s Global Head of Strategic Development, commented: “We are thrilled to receive this accreditation as it allows our current and future clients in France to benefit from a tax relief of up to 30% of their R&D expenditure committed to Precision for Medicine.”
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with over 3,000 employees in 40 locations across North America, Europe and APAC. For more information, visit precisionformedicine.com.
# # #
Contact:
Estelle Roger, Precision Medicine Group Senior Program Manager
estelle.roger@precisionmedicinegrp.com